The approval was based on a single-arm phase II FIGHT-202 trial, which evaluated patients with unresectable or metastatic CCA with FGFR2 gene fusions or rearrangements, who progressed on at least one prior therapy [77]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.